MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Sartorius Stedim Biotech S.A.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion - Sartorius Stedim Biotech S.A. (SSB) has been selected by ABL Europe as its primary supplier of single-use systems - ABLInc.com / Sartorius-Stedim.com
Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

 

NewswireToday - /newswire/ - Goettingen, Germany, 2018/03/16 - Sartorius Stedim Biotech S.A. (SSB) has been selected by ABL Europe as its primary supplier of single-use systems - ABLInc.com / Sartorius-Stedim.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Sartorius Stedim Biotech S.A. (SSB), a leading international technology partner of the biopharmaceutical industry, has been selected by ABL Europe as its primary supplier of single-use systems. Through a supply partnership with SSB, ABL Europe has successfully increased and brought online new viral vector manufacturing capacity at its European facility in Strasbourg. A subsidiary of ABL Inc., ABL Europe provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine and gene therapy projects in all stages of clinical development through to commercial launch.

Sartorius Stedim Biotech has delivered a comprehensive GMP viral vector manufacturing package solution that includes single-use bioreactors and an automation platform for normal flow filtration, tangential filtration and mixing. These have been installed at the facility, which is now in the process of manufacturing batches of viral vector products for ABL’s clients. Sartorius Stedim Biotech’s end-to-end process solutions in single-use (SU) format have helped ABL expand its existing drug substance capacity, with a fully disposable manufacturing capability for different viral vector product types produced in non-adherent cell lines.

Amélie Boulais Raveneau, Vaccine Platform Marketing Manager at SSB, commented: “We’re very proud to have been selected by ABL Europe to supply single-use process technologies and analytics specifically designed for use throughout ABL’s viral vector manufacturing process train. It is a significant endorsement of SSB’s platform for viral vector processing and the single-use design capabilities of the Sartorius Integrated Solutions engineering team. Our process development consultants share their expertise with clients to ensure optimal implementation of our technologies and overcome challenges in viral vector applications.”

Patrick Mahieux, General Manager of ABL Europe, has considerable experience in virus manufacturing including senior positions at Sanofi, Guerbet and Transgene. He said,“The introduction of non-adherent cell culture capacity complements our existing adherent cell culture viral vector production technologies. It is the only pure-play, dedicated viral vector production site capable of manufacturing drug substance and drug product materials for toxicological studies, all clinical phases and even commercial launch. Everything from process development, manufacturing and QC release testing is performed under one roof.”

To learn more about the facility, visit: vimeo.com/246296559


A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech (sartorius-stedim.com) is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2017, the company employed approx. 5,100 people, and earned sales revenue of €1,081.0 million.

About ABL Europe

ABL Europe (ableurope.com), a subsidiary of ABL, Inc. (ablinc.com) under the corporate ownership of Institut Mérieux, offers clinical and commercial scale GMP manufacturing of viral vectors for supply of gene therapy, oncolytic and vaccine products for use in all stages of product development globally. From its state-of-the-art GMP facility located in Strasbourg, France, ABL Europe's aseptic processing capabilities for drug substance and drug product, includes stirred single use bioreactors (SUB) < 500 L, adherent capacity in roller bottles or cell stacks < 90 m2, and automated filling using a rigid isolator < 10,000 vials per batch. ABL Europe is collaborating with an expanding client base supporting projects in phase 1/2 development, in addition to providing process validation and product supply for phase 3 / pivotal efficacy studies.

ABL Europe Contact: E: contact[.]ableurope.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sartorius Stedim Biotech S.A.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Petra Kirchhoff - Sartorius.com 
+49(0)551 308 1686 petra.kirchhoff[.]sartorius.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sartorius Stedim Biotech S.A. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sartorius Stedim Biotech S.A. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Huntington Study Group Ltd

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)